银屑病
伊米奎莫德
免疫学
肥大细胞
医学
白细胞介素17
特应性皮炎
炎症
发病机制
肿瘤坏死因子α
作者
Yiwen Hao,Delu Che,Bin Peng,Yi Zheng,Langchong He,Shuang Geng
标识
DOI:10.1016/j.jid.2020.03.077
摘要
Psoriasis is a chronic, inflammatory, polygenic disorder that is associated with both a physical and psychological burden. it is widely accepted that the IL23/Th17/IL17 axis is critical in the development of psoriasis, however, the pathogenesis of psoriasis is still not fully understood. Recent studies reported that mast cells increase and may be the main source of IL-17, IL22 in psoriatic lesions, whether mast cells participate in psoriasis need to be addressed. We used an imiquimod-induced mouse model of psoriasis-like dermatitis, the phenotype of which closely resembles the one observed in psoriasis patients. We found that wildtype mice treated with imiquimod had significantly increased and activated mast cells in their skin compared to control group, while the MrgprB2 knockout mice treated with IMQ had decreased and less activated mast cells, with decreased IL-17, IL-22, IL-23 and TNF-α levels. In vitro studies showed that imiquimod could activate MRGPRX2 in human mast cell and MrgprB2 in mouse mast cell. These results suggested that mast cells participated in the development of psoriasis-like dermatitis via MrgprB2 in mice, associated with the IL23/IL17 axis, which will help us understand the immunopathogenesis and provide new strategies for the prevention and treatment in psoriasis.
科研通智能强力驱动
Strongly Powered by AbleSci AI